title: Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis.
abstract: OBJECTIVE
  To evaluate the expression of apoptosis-related genes and their correlation with prognosis in cervical cancer patients.
  
  
  METHODS
  The expressions of Survivin, Fas and FasL in tissues of cervical cancer, cervical intraepithelial neoplasia (CIN), chronic cervicitis and normal cervix wer detected by immunohistochemical staining, and the relationship between the expression of Survivin, Fas and FasL and clinical pathologic characteristics of cervical cancer was correlation analysis.
  
  
  RESULTS
  The positive expression rates of Survivin and FasL in cervical cancer tissues were significantly higher than those in tissues of normal cervix, chronic cervicitis and CIN (p < 0.05), but lower positive expression rate of Fas was observed in cervical cancer tissues when compared with that in normal cervix, chronic cervicitis and CIN tissues (p < 0.05). The expression of Survivin was significantly correlated with clinical staging and lymph node metastases of cervical cancer (p < 0.05). The expression of FasL was correlated with lymph node metastases, clinical staging and pathological grading of cervical cancer (p < 0.05). The expression of Survivin was negatively correlated with that of Fas (r = -0.517, p < 0.01), but positively correlated with that of FasL (r = 0.381, p < 0.01) in tissues of cervical cancer.
  
  
  CONCLUSIONS
  The up-regulated expression of Survivin and FasL and down-regulated expression of Fas may be involved in the carcinogenesis and development of cervical cancer. The expression of FasL may be one of the prediction indexes for disease progression and prognosis in cervical cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Shanghai Jiaotong University, Shanghai, China. sfang_wu@hotmail.com
authors.forename: S-F
authors.initials: SF
authors.lastname: Wu
authors.forename: J-W
authors.initials: JW
authors.lastname: Zhang
authors.forename: W-Y
authors.initials: WY
authors.lastname: Qian
authors.forename: Y-B
authors.initials: YB
authors.lastname: Yang
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Dong
authors.forename: Z-B
authors.initials: ZB
authors.lastname: Zhang
authors.forename: Y-P
authors.initials: YP
authors.lastname: Zhu
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Feng
mesh_terms: D000328:Adult; D002584:Cervix Uteri / Q000737:chemistry; D053222:Fas Ligand Protein / Q000032:analysis* / Q000502:physiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis* / Q000502:physiology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D000077022:Survivin; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D019014:fas Receptor / Q000032:analysis* / Q000502:physiology
chemical_list: C107489:BIRC5 protein, human; D053222:Fas Ligand Protein; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D019014:fas Receptor